Business Wire

CapVest Enters Exclusive Discussions With HLD on the Proposed Acquisition of TSG

10.2.2026 09:00:00 CET | Business Wire | Press Release

Share

CapVest Partners LLP (“CapVest”), a leading New York and London based investment firm, and HLD, the entrepreneurial European investment group, have entered exclusive discussions on CapVest’s proposed acquisition of a majority stake in TSG, a European leader in technical services for critical energy infrastructure.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210375858/en/

Headquartered in Paris, France, TSG is a European leader in technical services for the energy industry with a pan-European footprint in over 30 countries and employing over 7,000 people. Originally focused on fuel station and private fleet energy infrastructure and systems, since HLD’s acquisition of the company in 2020 TSG has undergone significant transformation as a primary enabler of the energy transition, offering a diverse range of multi-energy technical services across Power (HV & LV electrical), Charge, Solar, Battery Energy Storage Systems (BESS), Biofuels and Gas & Biogas. Under HLD and management's leadership, annual revenues have grown to more than €1.4 billion with new energies accounting for approximately half of the revenue.

TSG’s current activities are focused on design, engineering and build, testing, equipment supply, maintenance and project management. As a result of these multi-energy capabilities, deep technical experience, and geographical coverage spanning 30 countries, TSG has established longstanding and trusted relationships with a diverse base of leading energy infrastructure operators, with many of these client relationships spanning several decades. TSG has achieved strong growth in recent years driven by positive medium- and long-term secular trends including the growing need for investment in critical energy infrastructure and the transition towards more sustainable multi-energy solutions.

As a leading private equity investor, CapVest is known for partnering with ambitious companies supplying essential goods and services and bringing deep sector expertise to its portfolio companies, making the firm ideally positioned to support TSG in its next phase of growth including accelerating organic growth and supporting further complementary acquisitions. Following completion of the proposed transaction, HLD and members of the management team will retain significant minority stakes in TSG, underscoring their confidence in the company’s future trajectory and commitment to supporting TSG’s ongoing growth.

Fred Raikes, Partner at CapVest, said: “We believe TSG is well positioned to accelerate international growth in the coming years, capitalising on its outstanding and highly skilled team, reputation for excellent quality of service and ongoing requirement of infrastructure operators to maintain, upgrade and provide more sustainable energy infrastructure and solutions. We look forward to working with Jean-Marc Bianchi and his team to build on their substantial successes to date and help unlock the very exciting growth opportunities ahead for TSG.”

Cédric Chateau, Partner and Chairman of the Investment Committee of HLD, said: “TSG has undergone a profound transformation and incredible acceleration during these past five years of HLD's shareholding alongside Jean-Marc Bianchi and his teams. The company has become a key player in the energy transition in Europe. The coming years are just as exciting for TSG, and we are delighted to extend this journey alongside the management and CapVest.”

Jean-Marc Bianchi, Chairman & CEO of TSG, said: “CapVest has an excellent reputation for working closely with management in transforming the size and scale of its portfolio companies and are an ideal next partner to work with us to realise our ambitious plans for the company. Their philosophy of undertaking significant investment in people, innovation and capabilities and focus on organic and acquisition led growth, strongly reflects our principles and plans and we very much look forward to working with them in the future. In the same vein, HLD have been excellent partners and we are very thankful for their contribution to all our successes to date and delighted they are still part of our journey.”

The transaction remains subject to the legal process of informing and consulting with relevant employee representative bodies, regulatory approvals in key jurisdictions where TSG operates, and other customary closing conditions.

The terms of the proposed transaction have not been disclosed.

Financial Advisors to CapVest were Perella Weinberg Partners and Rothschild & Co.

Financial Advisors to HLD were Amala Partners and Citi.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260210375858/en/

Contacts

For further information please contact:
On behalf of CapVest:
Ben Valdimarsson
Mob: +44 (0)7889 805930
bvaldimarsson@reputation-inc.com

On behalf of HLD:
DGM Conseil
Etienne Gautier
07 48 15 22 35
etienneg@dgm-conseil.fr

Charles-Etienne Lebatard
06 14 74 83 08
ce.lebatard@dgm-conseil.fr

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye